Wave Life Sciences (NASDAQ:WVE) said Takeda (NYSE:TAK) has elected not to exercise its option to further develop its Huntington’s disease treatment candidate WVE-003. As a result, Wave (WVE) is now ...
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results